[Form 4] Precigen, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Helen Sabzevari, President, CEO, and Director of Precigen, received a significant equity award of 500,000 Restricted Stock Units (RSUs) on June 26, 2025. This represents a substantial insider grant that aligns executive interests with shareholder value.

Key details of the RSU grant:

• Each RSU converts to one share of Precigen common stock
• Vesting schedule: 50% vests on May 23, 2026, with remaining vesting in equal monthly installments over three years
• Grant price: $0 (typical for RSU awards)
• Ownership form: Direct

This Form 4 filing indicates continued commitment to executive retention and long-term performance alignment through equity-based compensation. The extended vesting schedule suggests a focus on long-term value creation and executive retention.

Positive

• CEO Helen Sabzevari was granted 500,000 RSUs with a 4-year vesting schedule, representing significant long-term alignment with shareholder interests

Negative

• None.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabzevari Helen

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MD 20876

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/26/2025		A		500,000		(2)	(2)	Common Stock	500,000	$0	500,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

2. The RSUs vest 50% on May 23, 2026 and in equal monthly installments for three years thereafter.

	/s/ Helen Sabzevari, by Donald P. Lehr, as attorney-in-fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Restricted Stock Units (RSUs) did PGEN's CEO Helen Sabzevari receive on June 26, 2025?

Helen Sabzevari, President and CEO of Precigen (PGEN), received 500,000 Restricted Stock Units (RSUs) on June 26, 2025. Each RSU represents a contingent right to receive one share of Precigen common stock.

What is the vesting schedule for PGEN CEO's June 2025 RSU grant?

The RSUs granted to Helen Sabzevari vest 50% on May 23, 2026 (approximately 11 months after grant), and the remaining 50% vest in equal monthly installments over the following three years.

What was the purchase price of the RSUs granted to PGEN's CEO in June 2025?

The Restricted Stock Units were granted to Helen Sabzevari at a price of $0, as indicated in the Form 4 filing under the 'Price of Derivative Security' column.

What positions does Helen Sabzevari hold at PGEN according to the June 2025 Form 4?

According to the Form 4 filing, Helen Sabzevari serves as both a Director and an Officer (specifically President and CEO) of Precigen, Inc. (PGEN).